Patients want health systems to be more involved in their health
Physician involvement can determine how much patients benefit from services provided.
After Recruiting Oncology Nurses, Focus on Retention
Encourage professional development, foster resiliency, and engage nurse leaders to create an environment that not only brings in new nurses, but keeps them.
Caring for a Patient With Relapsed Mantle Cell Lymphoma Undergoing CAR T-Cell Therapy
CAR T-cell therapy represents a viable treatment option for many patients,
but there are potentially serious adverse events.
Challenges Faced by Adolescent and Young Adult Patients With Cancer
Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.
Advances in Head and Neck Cancers Yield New Clinical Implications for Nurses
As the treatment paradigm continues to evolve, nurses play a key role in educating patients, monitoring treatments, and watching for adverse effects.
Will Biden’s “Enhancing Oncology Model” Improve Outpatient Care for Medicare Patients?
The new model of care will seek to increase value-based care for patients receiving chemotherapy.
Cancer Has No Gender: Challenging Assumptions and Improving Quality of Care for the LGBTQ+ Community
Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.
FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC
The combination of durvalumab and tremelimumab has been approved for patients with unresectable hepatocellular carcinoma. The combination comes with warnings for immune-related adverse events and infusion reactions.
Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers
Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.
Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients
The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512